Last reviewed · How we verify
Endostar continuous intravenous infusion
Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors.
Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors. Used for Non-small cell lung cancer (NSCLC), Other solid tumors (in development).
At a glance
| Generic name | Endostar continuous intravenous infusion |
|---|---|
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Drug class | Angiogenesis inhibitor |
| Target | VEGF signaling pathway; endothelial cells |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Endostar is a truncated form of human endostatin, an endogenous angiogenesis inhibitor derived from collagen XVIII. It works by suppressing vascular endothelial growth factor (VEGF)-mediated endothelial cell proliferation and migration, thereby starving tumors of their blood supply. This anti-angiogenic mechanism reduces tumor growth and metastatic potential.
Approved indications
- Non-small cell lung cancer (NSCLC)
- Other solid tumors (in development)
Common side effects
- Hypertension
- Proteinuria
- Thromboembolism
- Hemorrhage
- Infusion-related reactions
Key clinical trials
- Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial (PHASE2)
- Local Injection and Systemic Therapy in the Treatment of NSCLC. (PHASE2)
- A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom (PHASE4)
- PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy (PHASE1)
- Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment (PHASE2)
- Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC (PHASE4)
- Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC (PHASE2)
- Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: